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A B S T R A C T   
The efficacy of Acceptance and Commitment Therapy (ACT) has been evaluated in many randomized controlled 
trials investigating a broad range of target conditions. This paper reviews the meta-analytic evidence on ACT. 
The 20 included meta-analyses reported 100 controlled effect sizes across n = 12,477 participants. Controlled 
effect sizes were grouped by target conditions and comparison group. Results showed that ACT is efficacious for 
all conditions examined, including anxiety, depression, substance use, pain, and transdiagnostic groups. Results 
also showed that ACT was generally superior to inactive controls (e.g. waitlist, placebo), treatment as usual, and 
most active intervention conditions (excluding CBT). Weaknesses and areas for future development are 
discussed.   
1. Introduction 
Acceptance and Commitment Therapy (ACT) aims to decrease 
suffering and increase well-being via six core processes of change 
(Hayes, Strosahl, & Wilson, 2012). In the thirty years since the first study 
on ACT was published (Zettle & Hayes, 1986), over 325 randomized 
controlled trials have been conducted (Hayes, 2019). From its seeds in 
North America, the proliferation of ACT trials has resulted in empirical 
studies from South America, Europe, Asia, Africa, and Australia. Such 
impressive growth is matched by positive results, with most studies 
reporting results that favor ACT. To date, no counterindications or iat-
rogenic effects have been reported to our knowledge, though they have 
not been extensively studied in an explicit manner. Nevertheless, some 
studies have reported that ACT performed less well compared to a 
control group in some comparisons. For example, five studies found that 
outcomes were not significantly different compared to either treatment 
as usual, cognitive behavioral therapy (CBT), befriending, or waitlist 
control (Craske et al., 2014; Plumb Vilardaga, 2013; Shawyer et al., 
2012; Wetherell et al., 2011; White et al., 2011). Other studies showed 
different change trajectories between ACT and the control condition. In 
one study, ACT was superior to CBT at posttreatment but not 
significantly different at a 3-months follow-up timepoint (Avdagic, 
Morrissey, & Boschen, 2014) and in another, ACT was inferior at post-
treatment but superior to CBT at 6-months follow-up (Lanza, García, 
Lamelas, & González-Menéndez, 2014). Furthermore, the quality of 
studies within the ACT literature varies greatly, a fact criticized in the 
literature (Linardon, Gleeson, Yap, Murphy, & Brennan, 2019; Öst, 
2014). Thus, there is a need to systematically examine the current 
literature and, further, to assess the methodological quality of this 
evidence. 
Matching the development of randomized controlled studies is the 
growth of reviews and meta-analyses that have examined ACT. To date, 
over 60 such papers have examined ACT within various topics ranging 
from clinical psychology to behavioral health. Many of the reviews and 
meta-analyses examine ACT in combination with other interventions 
such as dialectic behavioral therapy, mindfulness-based cognitive ther-
apy, or behavior activation depending on the purpose of the study. This 
fact makes it difficult to determine the efficacy of ACT in isolation. 
Furthermore, many reviews and meta-analyses examine the effect of 
ACT in a single group of diagnoses (e.g., depression, anxiety, psychosis, 
etc.). Whereas this is common in the literature, the theoretical basis of 
ACT is transdiagnostic and thus it is important to systematically examine 
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the full breadth of studies that exist in order to determine if ACT is 
equally efficacious across diagnoses or if ACT is less efficacious for some 
conditions. Furthermore, the theoretical basis of ACT suggests that 
outcomes of interest in intervention studies should not focus (exclu-
sively) on symptoms or diagnoses, as has been done traditionally in the 
larger psychotherapy literature, but rather measure the degree to which 
ACT improves participants’ functioning and well-being. 
Summary claims of ACT’s efficacy – as with any intervention – are 
also relative, in that the reported effect sizes are impacted by the com-
parison group used to determine the effect size. For example, an un-
controlled effect size (i.e., within group, pre-post comparison) will 
almost always be larger than controlled effect sizes (i.e., comparison to 
changes seen in participants in an alternate condition). Likewise, the 
between-group effect sizes differ as a function of the comparison group. 
It is therefore necessary to systematically compare ACT across various 
diagnostic categories and comparison groups in order to determine their 
impact on observed effect sizes. 
With these considerations in mind, the aim of the present study was 
to answer the question: what are the aggregated effect sizes of ACT vs. 
control groups, and by target conditions, across published meta- 
analyses. Towards this end, we reviewed the existing meta-analytic 
evidence of effect sizes for ACT factoring in control group and target 
condition. Specifically, we only included meta-analyses reporting 
between-condition analyses (controlled effect sizes) and where ACT was 
tested in isolation (e.g., not grouped together with other therapies). 
2. Method 
2.1. Selection of meta-analyses 
A systematic literature search was conducted by the second author 
on August 30th, 2019 to identify meta-analyses of ACT. In electronic 
databases (Ovid Medline®, PsycArticles, PsycInfo, Web of Science, and 
the compilation on the webpage of the Association of Contextual 
Behavioral Science (ACBS, 2020)) the following search terms were used: 
“acceptance”, “commitment”, “therapy”, “meta”, and “analysis”. These 
searches yielded 53 results. An additional 14 meta-analyses were iden-
tified in reference lists or via hand search. Overall the literature search 
yielded 67 results. Inclusion criteria for this review were: 1) written in 
English, 2) included meta-analytic analyses of randomized controlled 
trials comparing ACT to active and/or inactive control conditions, and 
3) published in a peer-reviewed journal. 
During a first screening process of the 67 initial manuscripts, 44 were 
excluded because 2 meta-analyses were not written in English, 3 were 
comments on or author’s responses to a published meta-analysis, 16 
were reviews and did not report any controlled meta-analytic effect 
sizes, 16 did not include at least one effect size for ACT compared to 
another condition, 2 were not peer-reviewed, 2 meta-analyses investi-
gated psychological flexibility processes exclusively in the lab (rather 
than RCTs), and 2 only described the protocol of the meta-analysis (for 
more details see flowchart in Fig. 1). After the extraction (see next 
section) three more meta-analyses were excluded because they did not 
report effect sizes for ACT alone compared to inactive/active conditions 
(instead they combined ACT with other mindfulness-based and modern 
cognitive behavioral treatments). 
Fig. 1. Flowchart describing literature search and processing.  
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2.2. Extraction and rating 
After the first screening process, the information of each remaining 
meta-analysis was extracted. We extracted effect sizes for different 
outcome measures, over different control conditions, and the number of 
comparisons these effect sizes included. In some cases, different effect 
sizes were given for the same comparison (e.g., ACT compared to 
waitlist). In these instances, the smallest effect size was chosen. For 
example, when outliers were omitted, the effect size without the outliers 
was the one extracted if it had a smaller effect size than the one with 
outliers. 
In a first step, we grouped the effect sizes according to the investi-
gated target condition. If a meta-analysis combined studies looking at 
different target conditions, we classified the reported effect size as 
transdiagnostic. This resulted in the following target conditions: 
depression (n = 15), anxiety (n = 11), substance abuse (n = 6), chronic 
pain (n = 8), transdiagnostic combinations of conditions (n = 24), all 
other conditions (n = 10), and other outcomes such as quality of life (n 
= 26). 
In a second step, three independent raters (first, third and last 
author) rated the intervention or control condition ACT was compared 
to, for all effect sizes reported within the identified meta-analyses. 
Comparison groups were waitlist (WL), cognitive behavior therapy 
(CBT), active treatments not including CBT (active), treatment as usual 
(TAU), placebo, or a combination of different non-active control groups 
that includes WL, TAU, and placebo when they were not analyzed 
separately in the meta-analyses (combined control conditions). After 
this rating, differences were examined, discussed, and a consensus 
grouping was reached. All raters agreed with the final rating. The aim of 
the rating was to cluster the effect sizes based on their comparison group 
and to see how ACT performs compared to different control conditions. 
Within all included meta-analyses 100 comparisons were identified, 
Table 1 
Results of the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR 2) quality assessment.  
Meta-Analysis AMSTAR 2 Items  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Öst (2008) No No Yes Partial 
yes 
No No No Partial 
Yes 
Yes No Yes No Yes Yes Yes No 
Powers, Zum Vörde Sive Vörding, and 
Emmelkamp (2009) 
No No No Partial 
yes 
No No No Partial 
Yes 
Yes No Yes Yes Yes Yes Yes No 
Veehof et al. (2011) Yes No No Partial 
yes 
Yes Yes No Partial 
Yes 
Yes No Yes No Yes No Yes Yes 
(Ruiz (2012)) Yes No Yes Partial 
yes 
No No Yes Partial 
Yes 
No No Yes No Yes Yes Yes No 
Bluett et al. (2014) No No No Partial 
yes 
No No No Partial 
Yes 
No No Yes No Yes No No No 
Öst (2014) No No Yes Partial 
yes 
No No No Partial 
Yes 
Yes No Yes No Yes No Yes No 
A-Tjak et al. (2015) No No No Yes Yes No No Partial 
Yes 
Yes No Yes Yes Yes Yes Yes No 
(Hacker et al. (2016)) Yes No No Partial 
yes 
Yes Yes No Partial 
Yes 
Yes No Yes No No No Yes Yes 
Lee, An, Levin, and Twohig (2015) Yes No No Partial 
yes 
No Yes No Partial 
Yes 
No No Yes No Yes No Yes Yes 
Brown, Glendenning, Hoon, and John 
(2016) 
Yes No No Partial 
yes 
Yes No No Partial 
Yes 
Yes No Yes No Yes No No Yes 
Spijkerman et al. (2016) Yes No No Partial 
yes 
Yes Yes No Yes Yes No Yes Yes Yes Yes Yes No 




Yes No No Partial 
Yes 
No No Yes No Yes No No No 




Yes No No Yes Yes No Yes No Yes No Yes Yes 
French et al. (2017) Yes No No Yes Yes No No Partial 
Yes 
Yes No Yes Yes Yes Yes Yes No 
Hughes et al. (2017) Yes Yes No Yes No No Yes Yes Yes No Yes No Yes Yes No No 
Rogers, Ferrari, Mosely, Lang, and Brennan 
(2017) 
Yes No No Partial 
yes 
Yes Yes No Yes No No Yes No Yes Yes Yes Yes 
Reeve et al. (2018) Yes No Yes Partial 
yes 
No No No Partial 
Yes 
Yes No Yes No Yes Yes Yes No 
Howell and Passmore, (2019) Yes No No Partial 
yes 
No No No Partial 
Yes 
No No Yes No Yes No Yes No 
Ii et al. (2019) Yes Yes No Partial 
yes 
Yes Yes No Yes Yes No Yes Yes Yes Yes No Yes 
Linardon et al. (2019 Yes No No Partial 
yes 
No No No Partial 
Yes 
Yes No Yes No Yes No Yes Yes 
Notes: Item 1) Did the research questions and inclusion criteria for the review include the components of PICO?; Item 2) Did the meta-analysis contain an explicit 
statement that the methods were established prior to the conduct of the meta-analysis and did the meta-analysis justify any significant deviations from the protocol?; 
Item 3) Was an explanation about the selection of the study designs for inclusion included in the meta-analysis?; Item 4) Was a comprehensive literature search strategy 
used?; Item 5) Was the study selection performed in duplicate?; Item 6) Was the data extraction performed in duplicate?; Item 7) Was a list of excluded studies with 
justification for the exclusions provided?; Item 8) Were the included studies described in adequate detail?; Item 9) Did the authors of the meta-analysis use a satis-
factory technique for assessing the risk of bias (RoB) in individual studies that were included in the review?; Item 10) Did the authors of the meta-analysis report on the 
sources of funding for the studies included in the review?; Item 11) Were appropriate methods used for statistical combination of results?; Item 12) Was the potential 
impact of RoB in individual studies on the results of the meta-analysis assessed?; Item 13) Did the authors of the meta-analysis account for RoB in individual studies 
when interpreting/discussing the results of the review?; Item 14) Was a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the 
review provided?; Item 15) Did the authors of the meta-analysis carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact 
on the results of the review?; Item 16) Did the authors of the meta-analysis report any potential sources of conflict of interest, including any funding they received for 
conducting the review?. 
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which were split as follows: n = 12 comparison to CBT, n = 22 com-
parisons to another active intervention, n = 13 comparisons to TAU, n =
11 comparisons to WL, n = 3 comparisons to placebo, and n = 39 
comparisons to combined control conditions. 
For the final sample of 20 meta-analyses, the third and fourth author 
independently performed a quality assessment using the validated 
Assessing the Methodological Quality of Systematic Reviews 2 
(AMSTAR-2) checklist. The AMSTAR-2 checklist includes 16 items 
focusing on the use of PICO as inclusion criteria, the prior registration of 
the review designs, how studies were selected and excluded, how the 
data was extracted, how the authors accounted for biases in their 
selected studies, the statistical analyses and the funding of the review as 
well as conflicts of interests (Shea et al., 2017). All items can be found in 
the notes of Table 1. 
Outcomes were determined by means of various standardized in-
terviews, questionnaires, behavioral or biological measurements. A 
detailed list of all measures across all comparisons is provided in 
Table 2. 
All effect sizes in this review are reported in hedges g or are other-
wise indicated. We first extracted the effect sizes as they were in the 
original meta-analyses. Effect sizes originally reported in Cohen’s d were 
transformed into Hedge’s g using the ‘esc’ package in R (Lüdecke, 2018) 
to increase comparability between effect sizes from different 
meta-analyses. Cohen’s d and Hedge’s g are very similar, however, in 
small sample sizes Hedge’s g outperforms Cohen’s d (Ellis, 2010). To 
simplify the interpretation of the results, U3 scores are also provided. U 
scores were introduced by Cohen (1988) as a measure of nonoverlap. A 
U3 score describes the percentage of the control group (e.g., CBT, Active, 
TAU, WL) that is exceeded by the upper half of the experimental group 
(ACT). Each U3 score corresponds to a specific effect size. For example, 
an effect size of 0 would correspond to a U3 score of 50% and an effect 
size of 1 would correspond to a U3 score of 84%. To illustrate the 
meaning of a U3 score, a U3 score of 84% signifies that the outcome of an 
average ACT patient is superior to the outcome of 84% of the patients in 
the control group. In each result section the effect sizes as well as the 
range of the U3 scores are given. Consider also Table 3, to see how a 
single effect size is expressed as a U3 score. 
To further illustrate the results, we report an overall mean effect size 
of the different effect sizes described within each target condition or 
comparison condition. The overall mean effect size was determined by 
the arithmetic mean of the individual effect sizes. These numbers should 
be read with caution, since they could not be weighted for number of 
participants as is done in primary meta-analyses. 
3. Results 
3.1. Sample 
The final sample consisted of 20 meta-analyses, which were based on 
133 studies and 12,477 participants. The individual studies that were 
reviewed in the meta-analyses spanned from 1986 (Zettle & Hayes, 
1986) to 2018 (Grégoire, Lachance, Bouffard, & Dionne, 2018). Some 
studies were used in more than one meta-analysis. In order to under-
stand the extent that individual studies were used in multiple 
meta-analyses (“double-dipping”), we examined all included studies in 
each meta-analysis and reviewed how many times each constituent 
study was used across all the included meta-analyses. More than half of 
the studies were included in only one meta-analysis. A third of the 
studies were used in two to four meta-analyses, a few were used five to 
seven times, and one study (Lundgren, Dahl, Melin, & Kies, 2006) was 
used ten times. The amount of unique studies in each meta-analysis 
varied greatly. Some of the more current meta-analyses report up to 
85% unique studies (Reeve, Tickle, & Moghaddam, 2018), though one 
reported no unique studies (Ii et al., 2019). Newer meta-analyses have a 
greater chance of including unique studies (because new studies are 
continually being reported), while some of the older metanalyses no 
longer contain any unique studies as a function of their age (Tonarelli, 
Pasillas, Alvarado, Dwivedi, & Cancellare, 2016; Veehof, Oskam, 
Schreurs, & Bohlmeijer, 2011; Öst, 2008). 
The methodological quality of the included meta-analyses were 
assessed using the AMSTAR-2 checklist (Shea et al., 2017). All or nearly 
all of the included meta-analyses reported on information assessed in the 
checklist with respect to: literature search (item 4), details of the 
included studies (item 8), appropriate statistical methods (item 11), and 
accounted for risk of bias in interpretation (item 13). None or next to 
none of the meta-analyses included information about: details of 
excluded studies (item 7) and information on the funding source (item 
10). The other information assessed by the checklist was included in 
some to most of the included meta-analyses (range 4–15 of the 
meta-analyses) (see Table 1 for details). 
Over all comparisons analyzed in this review, only four comparisons 
resulted in U3 scores that were below 50%, meaning that for these four 
comparisons the outcome of an average patient in the ACT condition is 
superior to the outcome of less than 50% of the patients in the control 
condition. In 19 comparisons U3 scores ranging from 50.0% to 59.9% 
were found, 44 comparisons had U3 scores from 60.0% to 69.9%, 24 
comparisons had U3 scores from 70.0% to 79.9% and 4 comparisons 
indicated U3 scores higher than 80.0%. For the remaining 5 compari-
sons, the effect sizes were given in risk ratios that could not be translated 
into U3 scores from the information provided. 
3.2. Outcomes of symptom reduction by target conditions 
The findings are presented for symptom reduction measures by 
condition. 
Depression (15 effect sizes). Nine meta-analyses were included in 
this review that reported on the effects of ACT for depression. Most (6 of 
9) presented with significant effect sizes favoring ACT (range of ES g =
0.24- 0.76; small to medium ES) compared to active (e.g., TAU, all active 
psychological interventions except CBT) and inactive (e.g., waitlist, 
placebo) conditions. The overall mean ES was small, g = 0.33. Two of the 
meta-analytic studies favored the control condition, however both were 
non-significantly better than ACT for depression (Reeve et al., 2018 
compared to combined control groups; Veehof, Trompetter, Bohlmeijer, 
& Schreurs, 2016 compared to CBT). The U3 scores for depression 
ranged from 39.7% to 79.7%. 
Anxiety (11 effect sizes). Seven meta-analyses were included that 
reported effects of ACT for anxiety spectrum disorders. Six of these 
presented with significant effect sizes favoring ACT with small to me-
dium ES (g = 0.18-0.57) compared to comparison conditions. Only one 
meta-analysis favored active control conditions (Hacker, Stone, & 
Macbeth, 2016), however the effect was negligible and non-significant 
(g = 0.04, p > .05). The overall mean ES was small, g = 0.24. The U3 
scores for anxiety ranged from 48.4% to 71.6%. 
Substance use (6 effect sizes). Only three meta-analyses were 
included that reported effects of ACT for substance use. Two of these 
significantly favored ACT with small effect sizes (g = 0.40-0.45) 
compared to other active interventions. The overall mean ES was small, 
g = 0.41. None of the studies favored the control conditions. The U3 
scores for substance use ranged from 63.3% to 67.4%. 
Chronic Pain (8 effect sizes). Two meta-analyses were included in 
this review that evaluated ACT for chronic pain, both of which focused 
on studies comparing ACT to active interventions, CBT, and a combi-
nation of inactive control conditions. There was a significant and large 
effect favoring ACT for one meta-analysis (Hughes, Clark, Colclough, 
Dale, & McMillan, 2017; g = 0.83), whereas for the other meta-analysis 
the effects were non-significant (Veehof et al., 2016). The overall mean 
ES was small, g = 0.44. The U3 scores for pain ranged from 49.2% to 
82.6%. 
Transdiagnostic combinations of conditions (24 effect sizes). 
Five meta-analyses were included that examined the effects of ACT 
transdiagnostically across a range of conditions compared to active and 
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Table 2 
Meta-analyses of acceptance and commitment therapy outcome measures.  
Meta-analysis Number of effect 
sizes in Comparisons 
Outcome cluster Comparison 
group 
Timepoint Outcome Measures 
Öst (2008) 8 Transdiagnostic Active Post Specific measures not listed 
5 Transdiagnostic TAU Post Specific measures not listed 
2 Transdiagnostic WL Post Specific measures not listed 
Powers et al. 
(2009) 
9 Transdiagnostic TAU Post BEST, CGI, DERS, Delusions, DSHI, Glycated hemoglobin, 
Hallucinations, Pain, Rehospitalization, Self-reported diabetes self- 
care, Smoking cessation, Stress symptoms hemoglobin 
4 Transdiagnostic WL Post BDI, BMI, Hairs pulled, Job satisfaction/motivation, MGH-HS, Weight 
Stigma Questionnaire 
8 Transdiagnostic Active Post ASI, BAI, BDI, HDRS, Job satisfaction/motivation, MARS, Pain, Self- 
reported use, SCL-90, TAI, Urine analysis 
2 Depression Combined Post BDI, HDRS 
5 Other Conditions: Physical 
Health 
Combined Post BMI, Glycated hemoglobin, Pain, Self-reported diabetes self-care, 
Seizure frequency, Seizure index, Stress symptoms, Weight Stigma 
Questionnaire, 
7 Transdiagnostic Combined Post ASI, BEST, CGI, DERS, Delusions, DSHI, Hallucinations, Hairs pulled, 
MGH-SH, Rehospitalization, Self-reported use, Smoking cessation, 
Urinanalysis 
4 Transdiagnostic Combined Post BAI, BDI, Job satisfaction/motivation, MARS, SCL-90, TAI 
Veehof et al. 
(2011) 
2 Pain Combined Post HADS, Pain, PDI, SWLS 
(Ruiz (2012)) 16 Transdiagnostic CBT Post and 
FU 
BAI, BDI, CSR, FACT-Breast, FNE, FQ, HRSD, Mood Visual Scale, 
QOLI, QOLS, SASS, SIAS, SF-36, SPS, SUD, VSLS, WILL, Y-BOCS 
10 Depression CBT Post and 
FU 
BDI, HRSD, Mood Visual Scale, SASS 
9 Anxiety CBT Post and 
FU 
BAI, CSR, FNE, FQ, HAS, MARS, PSWQ, SIAS, SPS, STAI, SUD, TAI, 
WILL, Y-BOCS, 
11 Other Outcomes: Quality of 
Life 
CBT Post and 
FU 
FACT-Breast, QOLS, QOLI, SF-36, VSLS 
Bluett et al. 
(2014) 
7 Anxiety Active Post BAI, DASS, GAI, HADS, SCL-90-Anxiety, STAI-S 
5 Anxiety CBT Post BAI, DASS, GAI, HADS, SCL-90-Anxiety, STAI-S 
Öst (2014) 16 Transdiagnostic WL Post Specific measures not listed 
4 Transdiagnostic Placebo Post Specific measures not listed 
14 Transdiagnostic TAU Post Specific measures not listed 
30 Transdiagnostic Active Post Specific measures not listed 
22 Transdiagnostic CBT Post Specific measures not listed 
7 Transdiagnostic WL FU Follow-up Specific measures not listed 
3 Transdiagnostic Placebo Follow-up Specific measures not listed 
7 Transdiagnostic TAU Follow-up Specific measures not listed 
23 Transdiagnostic Active Follow-up Specific measures not listed 
17 Transdiagnostic CBT Follow-up Specific measures not listed 
A-Tjak et al. 
(2015) 
9 Transdiagnostic WL Post and 
FU 
AAQ, Average hairs pulled per day, BMI, Clinician severity rating, 
DASS, GHQ, Hours of viewing pornography, Mental health difficulties, 
MGH-HS, NIMH-TIS, PDI, Physical activity, PSWQ, Weekly Pain, 
Weight Stigma Questionnaire, Stress, THI 
5 Transdiagnostic Placebo Post and 
FU 
Confidence in coping with command hallucinations, Confidence to 
resist command hallucinations, LDQ, OMPQ, PANSS, Seizure 
frequency, THI, Y-BOCS 
12 Transdiagnostic TAU Post and 
FU 
ADAMS, BDI, BDI-II, Believability ratings, BEST, BPI, BPRS, BSQ, 
DSHI, Drug test, Drug use self-report, EDE-Q, FDI, ISS, GHQ, HbA1C, 
Hallucinations, Number of glucose control, MIDAS, MPQ-SF, PAIRS, 
Rehospitalization, Smoking Cessation Quit Rate, Self-management, 
SBEQ, THI, Understanding, VABS 
9 Transdiagnostic CBT Post and 
FU 
ASI, BAI, BDI, BPI, Drug test, Dysphoria, FQ, HDRS, Negative affect, 
Negative self, PSWQ, RADS-2, Somatic, THI 
30 Other Outcomes: 
Secondary Outcome 
CBT Post and 
FU 
Specific secondary outcome measures not listed 
19 Other Outcomes: Quality of 
Life 
CBT Post and 
FU 
Specific secondary outcome measures not listed 
23 Other Outcomes Process 
Measures 
Combined Post and 
FU 
Specific secondary outcome measures not listed 
8 Transdiagnostic TAU Post and 
FU 
Specific secondary outcome measures not listed 
8 Substance Abuse TAU Post and 
FU 
BDI-II, Drug Test, Drug use self-report, ISS, LDQ, Smoking Cessation 
Quit Rate 
15 Other Conditions: Somatic 
Complaints 
Combined Post and 
FU 
BMI, BSQ, CECS, COPE, GHQ, HbA1C, Mental health difficulties, 
MIDAS, MPQ-SF, Number in glucose control, OMPQ, Physical activity, 
POMS, Self-management, Seizure frequency/duration, THI, 
Understanding, Weekly pain 
(Hacker et al. 
(2016)) 
15 Depression Active Post BDI, CES-DC, DASS-D, HADS-D, 
10 Anxiety Active Post ASI, BAI, CSR, DASS-A, HADS-A, PASS, PSWQ, STAI 
28 Anxiety WL Post BAI, DASS-A, HADS-A, PAI-A, PSWQ, STAI, STAI-T 
39 Depression WL Post BDI, CES-D, DASS-D, GDS-10, HADS-D, PAI-D, PHQ-9, RADS-2 
Lee et al. (2015) 10 Substance Abuse Active Follow-up Substance abstinence 
(continued on next page) 
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Table 2 (continued ) 
Meta-analysis Number of effect 
sizes in Comparisons 
Outcome cluster Comparison 
group 
Timepoint Outcome Measures 
3 Substance Abuse Active (CBT) Follow-up Substance abstinence 
5 Substance Abuse: Smoking Active Post Substance abstinence 
5 Substance Abuse: Drugs Active Post Substance abstinence 
Brown et al. 
(2016) 
10 Depression Combined Post BDI, CES-D, DASS, HADS, MADRS-S 
7 Anxiety Combined Post BAI, DASS, HADS 
8 Other Outcomes: Quality of 
Life 
Combined Post GHQ-12, MHC-SF, QOLI, SCL-90 
Spijkerman et al. 
(2016) 
5 Depression Combined Post BDI-II, CES-D, DASS-D, HADS-D, PHQ-9-D, POMS-D 
5 Anxiety Combined Post BAI, DASS-A, HADS-A, POMS-A 
2 Other Conditions: Stress Combined Post CSOSI, DASS-S, PSS, PSQ 
4 Other Outcomes: Well- 
Being 
Combined Post MHC-SF, QOLI, SWLS, WHO-5, 
2 Other Outcomes: 
Mindfulness 
Combined Post CAMS-R, FFMQ, FMI, MAAS 
Tonarelli et al. 
(2016) 
2 Other Conditions: 
Psychosis (Negative 
Symptoms) 
TAU Post PANNS +
2 Other Conditions: 
Psychosis (Positive 
Symptoms) 
TAU Post PANNS - 
3 Other Conditions: 
Schizophrenia 
TAU Post Delusions, Emotional dysfunction, Hallucinations 
3 Other Conditions: Schizo- 
affective 
TAU Post Delusions, Emotional dysfunction, Hallucinations 
2 Other Outcomes: 
Rehospitalization 
TAU Post Rehospitalization Rate at 4-month follow-up 
Veehof et al. 
(2016) 
2 Pain CBT Post BPI-SF 
2 Depression CBT Post BDI 
3 Pain Active Post MPI, NRS, VAS 
3 Depression Active Post HADS 
2 Other Outcomes: Disability Active Post OMPQ, SF-36 PCS 
2 Other Outcomes: Quality of 
Life 
Active Post QOLI 
French et al. 
(2017) 
9 Depression Combined Post BDI-II, CES-D, DASS-21, CMDI, HADS 
8 Depression WL Post BDI-II, CES-D, DASS-21, CMDI, HADS 
8 Anxiety Combined Post BAI, DASS-21, HADS 
8 Anxiety WL Post BAI, DASS-21, HADS 
10 Other Outcomes: 
Psychological Flexibility 
Combined Post AAQ-II, AFQ-Y, AIS, CPAQ, PIPS, TAQ 
8 Other Outcomes: 
Psychological Flexibility 
WL Post AAQ-II, CPAQ, PIPS 
Hughes et al. 
(2017) 
3 Pain: Acceptance Combined Post BPCI-A, CPAQ 
6 Other Outcomes: Quality of 
Life 
Combined Post LSQ, QOLI, QOLS, SF-36, SWLS 
3 Other Outcomes: Quality of 
Life 
Combined Follow-up LSQ, QOLI, QOLS, SF-36, SWLS 
5 Other Outcomes: 
Functioning 
Combined Post PAIRS, PDI, RMDQ 
4 Other Outcomes: 
Functioning 
Combined Follow-up PAIRS, PDI 
4 Anxiety Combined Post HADS, STAI-S 
3 Anxiety Combined Follow-up HADS, STAI-S 
5 Depression Combined Post BDI, DASS, HADS, PHQ-9 
4 Depression Combined Follow-up BDI, DASS, HADS, PHQ-9 
2 Other Outcomes: 
Psychological Flexibility 
Combined Post PIPS 
2 Other Outcomes: 
Psychological Flexibility 
Combined Follow-up PIPS 
6 Pain: Intensity Combined Post MPI, NRS, PIR, VAS 
4 Pain: Intensity Combined Follow-up MPI, NRS, PIR, VAS 
2 Pain Active Post BPI-S, NRS 
2 Pain Active Follow-up BPI-S, NRS 
2 Other Outcomes: Quality of 
Life 
Active Post SF-12 PCS, SWLS 
2 Other Outcomes: Quality of 
Life 
Active Follow-up SF-12 PCS, SWLS 
2 Other Outcomes: 
Functioning 
Active Post BPI-I, OMPQ, PDI 
2 Other Outcomes: 
Functioning 
Active Follow-up BPI-I, OMPQ, PDI 
2 Depression Active Post BDI-II, HADS 
Rogers et al. 
(2017) 
3 Other Outcomes: Quality of 
Life 
Combined Post IWQOL-Lite, QOLI, WHOQOL 
Reeve et al. 
(2018) 
3 Depression Combined Post MBI, SSQ 
2 Depression Combined Follow-up MBI, SSQ 
(continued on next page) 
A.T. Gloster et al.                                                                                                                                                                                                                               
Journal of Contextual Behavioral Science 18 (2020) 181–192
187
inactive control groups. All resulted in significant small to large effect 
sizes in favor of ACT (g = 0.17-0.96). The overall mean ES was small, g 
= 0.46. The U3 scores investigating transdiagnostic conditions ranged 
from 51.2% to 83.1%. 
Other conditions (10 effect sizes). Individual meta-analyses were 
included that reported on other conditions, such as eating disorders (n =
1), psychosis (n = 1), stress (n = 2), somatic complaints (n = 1) and 
physical conditions (n = 1). Five of these reported significant small to 
medium ES for ACT compared to control conditions (g = 0.29- 0.64). In 
only one meta-analysis specifically for positive psychosis symptom-
atology there was a non-significant negligible effect in favor of the TAU 
control group compared to ACT (Tonarelli et al., 2016). The U3 scores 
investigating other conditions ranged from 44.0% to 73.9%. 
Other Outcomes (26 effect sizes). Regarding quality of life as an 
outcome of the interventions tested, 6 meta-analyses were found and all 
reported effects in favor of ACT compared to active and inactive control 
groups. For three of these meta-analyses the effects were significant and 
medium ES (g = 0.37-0.45). For the rest (3 studies) there were non- 
significant differences between ACT and control conditions on quality 
of life. The overall mean ES was small g = 0.48. The U3 scores range from 
52.0% to 94.0%. 
Three meta-analyses examined intervention effects on psychological 
flexibility. Two of the studies significantly favored ACT compared to 
active and inactive control conditions with small to large ES (g = 0.32- 
0.83). In the (Reeve et al. (2018)) meta-analysis, ACT did not signifi-
cantly differ from other control conditions on psychological flexibility. 
The overall mean ES was small g = 0.42. The U3 scores range from 52.8% 
to 79.7%. 
Some meta-analyses (total n = 7) utilized different outcome mea-
sures (e.g., well-being, rehospitalization, physical health, mindfulness, 
functioning, and disability). Five of them presented with significant 
small to medium ES (g = 0.29-0.67) in favor of ACT. For the other two 
studies, ACT was not found to significantly differ on these outcomes 
(well-being; Spijkerman, Pots, & Bohlmeijer, 2016; and disability; 
Veehof et al., 2016). The overall mean ES was medium g = 0.57. The U3 
scores range from 56.7% to 99.4%. 
3.3. Findings by comparison conditions 
WL. Eleven effect sizes from seven meta-analyses compared ACT to 
WL. All 11 comparisons favored ACT and all were reported to be sta-
tistically significant. Effect sizes were calculated for outcomes of 
depression, anxiety, eating disorders, transdiagnostic conditions, and 
psychological flexibility. These outcomes were measured at post and 
follow up time points. The 11 meta-analytic effects comparing ACT to 
WL reported ESs ranging from small (g = 0.35; French, 
Golijani-Moghaddam, & Schröder, 2017) to large (g = 0.82; A-Tjak 
et al., 2015). The mean overall ES comparing ACT to WL corresponded 
to a medium effect (g = 0.57). The U3 scores range from 63.7% to 83.1%. 
Placebo. Three effect sizes from two meta-analyses compared ACT 
to placebo. Two of the three comparisons were reported to be statisti-
cally significant. All the effect sizes for comparisons between ACT and 
placebo were for transdiagnostic conditions. These outcomes were 
measured at post and follow up time points. All three meta-analytic 
effects reported for comparisons with placebo were medium effects 
sizes ranging from g = .51 (A-Tjak et al., 2015) to g = 0.59 (Öst, 2014). 
Table 2 (continued ) 
Meta-analysis Number of effect 
sizes in Comparisons 
Outcome cluster Comparison 
group 
Timepoint Outcome Measures 
3 Other Conditions: Stress Combined Post DSI, GHQ-12, GHQ-28, PANAS, WEMWBS 
2 Other Conditions: Stress Combined Follow-up GHQ-12, GHQ-28, WEMWBS 
3 Other Outcomes: 
Psychological Flexibility 
Combined Post AAQ-II, COPE, SSVQ, VLQ, WBSI 
2 Other Outcomes: 
Psychological Flexibility 




5 Other Outcomes: Well- 
Being 
Combined Post ABS, MHC-SF, WBMMS 
Ii et al. (2019) 3 Substance Abuse TAU Post Substance discontinuation 
Linardon et al. 
(2019) 
3 Other Conditions: Eating 
Disorders 
WL Post Binge eating frequency, BSQ, DEBQ, EAT, EDE, PEWS 
Notes: AAQ = Acceptance and Action Questionnaire, ABS = Affect Balance Scales, ADAMS = Anxiety, Depression, and Mood Scale, AFQ = Avoidance and Fusion 
Questionnaire for Youth, AIS = Avoidance and Inflexibility Scale, ASI = Addiction Severity Index, BAI = Beck Anxiety Inventory, BDI = Becks Depression Inventory, 
BEST = Borderline evaluation of severity over time, BMI = Body Mass Index, BPCI = Brief Pain Coping Inventory, BPI = Brief Pain Inventory, BPRS = Brief Psychiatric 
Rating Scale, BSQ = Body Shape Questionnaire, CAMS-R = Cognitive and Affective Mindfulness Scale Revised, CECS = Courtland Emotional Control Scale, CES-DC =
Centre for Epidemiological Studies Depression Scale for Children, CGI = Clinical Global Impression, CMDI = Chicago Multi-scale Depression Inventory, COPE =
Assessment of coping, CPAQ = Chronic Pain Acceptance Questionnaire, CSOSI = Calgary Symptoms of Stress Inventory, CSR = Clinical Severity Ratings, DASS =
Depression Anxiety Stress Scales, DEBQ = Dutch Eating Behavior Questionnaire, DERS = Difficulties in Emotion Regulation Scale, DSHI = Deliberate Self-harm In-
ventory, DSI = Daily Stress Inventory, EAT = Eating Attitudes Test, EDE-Q = Eating Disorders Examination Questionnaire, FACT = Functional Assessment of Cancer 
Therapy, FDI = Functional Disability Inventory, FFMQ = Five Facet Mindfulness Questionnaire, FNE = Fear of Negative Evaluation Scale, FQ= Fear Questionnaire, 
GAI = Geriatric Anxiety Inventory, GHQ = General Health Questionnaire, HADS = Hospital Anxiety and Depression Scale, HDRS = Hamilton Depression Rating Scale, 
ISS = Internalized Shame Scales, IWQOL = Impact of Weight on Quality of Life, LDQ = Leeds Dependence Questionnaire, LSQ = Life Satisfaction Questionnaire, MAAS 
= Mindful Attention Awareness Scale, MARS = Mathematics Anxiety Rating Scale, MBI = Maslach Burnout Inventory, MGH-HS = Massachusetts General Hospital 
Hairpulling Scale, MHC = Mental Health Continuum, MIDAS = Migraine Disability Assessment Scale, MPQ = McGill Pain Questionnaire, NIMH-TIS = NIMH- 
Trichotillomania Impairment Scale, NRS = Numerical Rating Scale, OMPQ = Örebro Muscoloskeletal Pain Questionnaire, PAI = Personality Assessment Inventory, 
PAIRS = Pain Impairment Relationship Scale, PANAS = Positive and Negative Affect Scale, PANSS = Positive and Negative Symptoms Scale, PASS = Pain Anxiety 
Symptom Scale, PCS = Physical Component Summary, PDI = Pain Disability Index, PEWS = Pediatric Early Warning Score, PHQ = Patient Health Questionnaire, PIPS 
= Psychological Inflexibility in Pain Scale, POMS = Profile of Mood States, PSS = Perceived Stress Scale, PSWQ = Penn State Worry Questionnaire, QOLI = Quality of 
Life Inventory, QOLS = Quality of Life Scale, RADS-2 = Reynolds Adolescent Depression Scale, RMDQ = Life Satisfaction Questionnaire, SASS = Social Adaptation Self- 
Evaluation Scale, SBEQ = Subjective Binge Eating Questionnaire, SCL-90 = Symptom Checklist-90, SF-36 = Short Form Health Survey, SIAS = Social Interaction 
Anxiety Scale, SPS = Social Phobia Scale, SSQ = Staff Stressor Questionnaire, SSVQ = Support Staff Values Questionnaire, STAI = State Trait Anxiety Inventory, SUD =
Subject Units of Discomfort, SWLS = Satisfaction with Life Scale, TAI = Test Anxiety Inventory, TAQ = Tinnitus Acceptance Questionnaire, THI = Tinnitus Handicap 
Inventory, VABS = Vineland Adaptive Behaviors Scales, VAS = Visual Analogue Scale, VLQ = Valued Living Questionnaire, VSLS = Visual Scale Life Satisfaction, 
WBMMS = Well-Being Manifestations Measure Scale, WBSI = White Bear Suppression Inventory, WEMWBS = Warwick-Edinburgh Mental Well-Being Scale, WHO-5 =
5 Item World Health Organization Well-Being Index, WHOQOL = World Health Organization Quality of Life, WILL = Willingness Scale, Y-BOCS = Yale-Brown 
Obsessive-Compulsive Scale. 
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Table 3 
Effect sizes of included meta-analyses of Acceptance and Commitment Therapy Outcomes.  
Meta-analysis Number of 
Comparisons 
Outcome cluster Comparison 
group 
Timepoint of comparison ES Significance U3 
(%) 
Öst (2008) 8 Transdiagnostic Active Post 0.53 Significant 70.2 
5 Transdiagnostic TAU Post 0.79 Significant 78.5 
2 Transdiagnostic WL Post 0.96 Significant 83.1 
Powers et al. (2009) 9 Transdiagnostic TAU Post 0.42 Significant 66.3 
4 Transdiagnostic WL Post 0.68 Significant 75.2 
8 Transdiagnostic Active Post 0.18 Not 
significant 
57.1 
2 Depression Combined Post 0.76 Significant 77.6 
5 Other Conditions: Physical Health Combined Post 0.39 Significant 65.2 
7 Transdiagnostic Combined Post 0.60 Significant 72.6 
4 Transdiagnostic Combined Post 0.03 Not 
significant 
51.2 
Veehof et al. (2011) 2 Pain Combined Post 0.28 Not 
significant 
61.0 
(Ruiz (2012)) 16 Transdiagnostic CBT Timepoints combined 
(Post and FU) 
0.40 Significant 65.5 
10 Depression CBT Timepoints combined 0.27 Not 
significant 
60.6 
9 Anxiety CBT Timepoints combined 0.14 Not 
significant 
55.6 
11 Other Outcomes: Quality of Life CBT Timepoints combined 0.22 Not 
significant 
58.7 
Bluett et al. (2014) 7 Anxiety Active Post 0.02 Not 
significant 
50.8 
5 Anxiety CBT Post 0.00 Not 
significant 
50.0 
Öst (2014) 16 Transdiagnostic WL Post 0.63 Significant 73.6 
4 Transdiagnostic Placebo Post 0.59 Not 
significant 
72.2 
14 Transdiagnostic TAU Post 0.55 Significant 70.9 
30 Transdiagnostic Active Post 0.22 Significant 58.7 
22 Transdiagnostic CBT Post 0.16 Not 
significant 
56.4 
7 Transdiagnostic WL Follow-up 0.39 Significant 65.2 
3 Transdiagnostic Placebo Follow-up 0.53 Not 
significant 
70.2 
7 Transdiagnostic TAU Follow-up 0.48 Significant 68.4 
23 Transdiagnostic Active Follow-up 0.17 Significant 56.7 
17 Transdiagnostic CBT Follow-up 0.06 Not 
significant 
52.4 
A-Tjak et al. (2015) 9 Transdiagnostic WL Timepoints combined 0.82 Significant 79.4 
5 Transdiagnostic Placebo Timepoints combined 0.51 Significant 69.5 
12 Transdiagnostic TAU Timepoints combined 0.64 Significant 73.9 
9 Transdiagnostic CBT Timepoints combined 0.32 Not 
significant 
62.6 
30 Other Outcomes: Secondary Outcome CBT Timepoints combined 0.30 Significant 61.8 
19 Other Outcomes: Quality of Life CBT Timepoints combined 0.37 Significant 64.4 
23 Other Outcomes: Process Measures Combined Timepoints combined 0.56 Significant 71.2 
8 Transdiagnostic TAU Timepoints combined 0.37 Significant 64.4 
8 Substance Abuse TAU Timepoints combined 0.40 Significant 65.5 
15 Other Conditions: Somatic 
Complaints 
Combined Timepoints combined 0.58 Significant 71.9 
(Hacker et al. (2016)) 15 Depression Active Post 0.26 not 
significant 
60.3 
10 Anxiety Active Post − 0.04 not 
significant 
48.4 
28 Anxiety WL Post 0.45 Significant 67.4 
39 Depression WL Post 0.54 Significant 70.5 
Lee et al. (2015) 10 Substance Abuse Active Follow-up 0.43 Significant 66.6 
3 Substance Abuse CBT Follow-up 0.34 Not 
significant 
63.3 
5 Substance Abuse: Smoking Active Post 0.42 Significant 66.3 
5 Substance Abuse: Drugs Active Post 0.45 Significant 67.4 
Brown et al. (2016) 10 Depression Combined Post 0.24 Significant 59.5 
7 Anxiety Combined Post 0.18 Significant 57.1 
8 Other Outcomes: Quality of Life Combined Post 0.06 Not 
significant 
52.4 
Spijkerman et al. 
(2016) 
5 Depression Combined Post 0.40 Significant 65.5 
5 Anxiety Combined Post 0.37 Significant 64.4 
2 Other Conditions: Stress Combined Post 0.34 not 
significant 
63.3 
4 Other Outcomes: Well-Being Combined Post 0.17 not 
significant 
56.7 
(continued on next page) 
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Table 3 (continued ) 
Meta-analysis Number of 
Comparisons 
Outcome cluster Comparison 
group 
Timepoint of comparison ES Significance U3 
(%) 
2 Other Outcomes: Mindfulness Combined Post 0.39 Significant 65.2 
Tonarelli et al. (2016) 2 Other Conditions: Psychosis (Positive 
Symptoms) 
TAU Post − 0.15 Not 
significant 
44.0 
2 Other Conditions: Psychosis 
(Negative Symptoms) 
TAU Post 0.64 Significant 73.9 








2 Other Outcomes: Rehospitalization TAU Post RR =
0.54 
Significant  
Veehof et al. (2016) 2 Pain CBT Post − 0.02 Not 
significant 
49.2 




3 Pain Active Post 0.94 Not 
significant 
82.6 
3 Depression Active Post 0.83 Not 
significant 
79.7 
2 Other Outcomes: Disability Active Post 2.52 Not 
significant 
99.4 
2 Other Outcomes: Quality of Life Active Post 1.55 Not 
significant 
93.9 
French et al. (2017) 9 Depression Combined Post 0.28 Significant 61.0 
8 Depression WL Post 0.40 Significant 65.5 
8 Anxiety Combined Post 0.30 Significant 61.8 
8 Anxiety WL Post 0.35 Significant 63.7 
12 Other Outcomes: Psychological 
Flexibility 
Combined Post 0.32 Significant 62.6 
8 Other Outcomes: Psychological 
Flexibility 
WL Post 0.52 Significant 69.8 
Hughes et al. (2017) 3 Pain: Acceptance Combined Post 0.52 Significant 69.8 
6 Other Outcomes: Quality of Life Combined Post 0.05 Not 
significant 
52.0 
3 Other Outcomes: Quality of Life Combined Follow-up 0.26 Not 
significant 
60.3 
5 Other Outcomes: Functioning Combined Post 0.45 Significant 67.4 
4 Other Outcomes: Functioning Combined Follow-up 0.41 Significant 65.9 
4 Anxiety Combined Post 0.57 Significant 71.6 
3 Anxiety Combined Follow-up 0.32 Not 
significant 
62.6 
5 Depression Combined Post 0.52 Significant 69.8 
4 Depression Combined Follow-up 0.52 Significant 69.8 
2 Other Outcomes: Psychological 
Flexibility 
Combined Post 0.83 Significant 79.7 
2 Other Outcomes: Psychological 
Flexibility 
Combined Follow-up 0.64 Significant 73.9 
6 Pain: Intensity Combined Post 0.26 Not 
significant 
60.3 
4 Pain: Intensity Combined Follow-up 0.29 Not 
significant 
61.4 
2 Pain Active Post 0.83 Significant 79.7 
2 Pain Active Follow-up 0.42 Significant 66.3 
2 Other Outcomes: Quality of Life Active Post 0.39 Significant 65.2 
2 Other Outcomes: Quality of Life Active Follow-up 0.45 Significant 67.4 
2 Other Outcomes: Functioning Active Post 0.67 Significant 74.9 
2 Other Outcomes: Functioning Active Follow-up 0.35 Significant 63.7 
2 Depression Active Post 0.35 Significant 63.7 
Rogers et al. (2017) 3 Other Outcomes: Quality of Life Combined Post 0.66 Not 
significant 
74.5 
Reeve et al. (2018) 4 Depression Combined Post − 0.26 Not 
significant 
39.7 
3 Depression Combined Follow-up 0.05 Not 
significant 
52.0 
4 Other Conditions: Stress Combined Post 0.29 Not 
Significant 
61.4 
3 Other Conditions: Stress Combined Follow-up 0.09 Not 
significant 
53.6 
3 Other Outcomes: Psychological 
Flexibility 
Combined Post 0.07 Not 
significant 
52.8 
2 Other Outcomes: Psychological 
Flexibility 
Combined Follow-up 0.16 Not 
significant 
56.4 
Howell and Passmore, 
(2019) 
5 Other Outcomes: Well-Being Combined Post 0.29 Significant 61.4 
Li et al. (2019) 3 Substance Abuse TAU Post  
(continued on next page) 
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The mean overall effect size comparing ACT to placebo corresponded to 
a medium effect (g = 0.54). The U3 scores range from 69.5% to 72.2%. 
Treatment as Usual (TAU). Thirteen effect sizes from six meta- 
analyses compared ACT to TAU. Twelve of the 13 comparisons 
favored ACT and 8 of the 13 comparisons were reported to be statisti-
cally significant. The one comparison that favored TAU was a non- 
significant effect for negative symptomatology in psychosis. Effect 
sizes were calculated for outcomes of substance abuse, psychosis (pos-
itive and negative symptoms), re-hospitalization, and quality of life. 
These outcomes were measured at post and follow up time points. The 
thirteen meta-analytic effects comparing ACT to TAU reported effects 
sizes ranging from no effect g = − 0.15 (Tonarelli et al., 2016) to medium 
g = 0.79 (Öst, 2014). The mean overall effect size comparing ACT to 
TAU corresponded to a small effect (g = 0.46). The U3 scores range from 
44.0% to 78.5%. 
Active Interventions (other than CBT). Twenty-two effect sizes 
from eight meta-analyses compared ACT to active interventions. 
Twenty-one of the 22 comparisons favored ACT and 14 of the 22 com-
parisons were reported to be statistically significant. The one compari-
son that favored the active condition was a non-significant effect for 
anxiety (Hacker et al., 2016). Effect sizes were calculated for outcomes 
of anxiety, depression, chronic pain, substance abuse, transdiagnostic 
conditions, functioning, disability, and quality of life. These outcomes 
were measured at post and follow up time points. The 22 meta-analytic 
effects comparing ACT to active interventions other than CBT reported 
effects sizes ranging from no effect in anxiety g = − 0.04 (Hacker et al., 
2016) to large in disability g = 2.52 (Veehof et al., 2016). The mean 
overall effect size comparing ACT to active interventions corresponded 
to a medium effect (g = 0.57). The U3 scores range from 48.4% to 99.4%. 
Cognitive Behavioral Therapy (CBT). Twelve effect sizes from five 
meta-analyses compared ACT to CBT. Ten of the 12 comparisons favored 
ACT and 3 of the 12 comparisons were reported to be statistically sig-
nificant. The two comparisons that favored CBT were non-significant 
effects for depression and chronic pain (Veehof et al., 2016). Effect 
sizes were calculated for outcomes of anxiety, depression, chronic pain, 
quality of life and secondary outcomes. These outcomes were measured 
at post and follow up time points. The 12 meta-analytic effects 
comparing ACT to CBT reported effects sizes ranging from no effect in 
anxiety g = 0.00 (Bluett, Homan, Morrison, Levin, & Twohig, 2014) to 
small in transdiagnostic outcomes g = 0.40 (Ruiz, 2012). The mean 
overall effect size comparing ACT to active interventions corresponded 
to a negligible effect (g = 0.16). The U3 scores range from 40.1% to 
65.5%. 
Combined Control Conditions. Thirty-nine effect sizes from 10 
meta-analyses compared ACT to a combination of control conditions (e. 
g. placebo, waitlist, TAU). Thirty-eight of the 39 comparisons favored 
ACT and 27 of the 39 comparisons were reported to be statistically 
significant. The one comparison that favored the combined control 
conditions was a non-significant effect for depression (Reeve et al., 
2018). Effect sizes were calculated for outcomes of anxiety, depression, 
other mental conditions, chronic pain, somatic complaints, stress, 
mindfulness, psychological flexibility, quality of life, well-being, func-
tioning, and other process measures. These outcomes were measured at 
post and follow up time points. The 39 meta-analytic effects comparing 
ACT to combined conditions reported effect sizes ranging from no effect 
in depression g = − 0.26 (Reeve et al., 2018) to a large effect for psy-
chological flexibility g = 0.83 (Hughes et al., 2017). The mean overall 
effect size comparing ACT to combined control conditions corresponded 
to a small effect (g = 0.33). The U3 scores range from 39.7% to 79.7%. 
4. Discussion 
As evidenced across 20 meta-analyses, 133 studies, and 12,477 
participants, ACT is efficacious. The evidence suggests that ACT is effi-
cacious across a broad range of intervention targets (e.g., diagnoses of 
mental disorders and health conditions such as chronic pain), with 
largely equivalent results across these areas. As expected, effect sizes 
were larger when compared to inactive control groups and smaller when 
compared to active control groups. Importantly, in this review we 
exclusively extracted and reported on controlled effect sizes (i.e., 
between-condition comparisons in RCTs) because these are the most 
conservative estimates. U3 scores, a measure of nonoverlap, were re-
ported as well to illustrate the effect sizes. The scores ranged from 40% 
comparing ACT to CBT to over 90% comparing ACT to another active 
intervention. 
The literature of treatment outcome studies has traditionally been 
organized around specific diagnoses, and meta-analyses have followed 
suit. In the present review we found multiple meta-analyses showing 
that ACT is associated with controlled effect sizes ranging from small to 
medium (with mean effect sizes in the small range) for target conditions 
of depression, anxiety, substance abuse, and chronic pain. Multiple 
meta-analyses also found that ACT is efficacious transdiagnostically for 
a range of conditions, again with small controlled effect sizes. Single 
meta-analyses further found evidence for eating disorders, stress, so-
matic complaints, and physical conditions, with small to medium 
controlled effect sizes. The consistent small to medium sized controlled 
effects across all target conditions suggests that ACT’s effects are largely 
uniform. The results of this review are consistent with the trans-
diagnostic theoretical basis of ACT. Nevertheless, in order to more fully 
test the transdiagnostic assumptions of ACT, future studies are needed. 
One type of study that is needed are meta-analyses that expand the types 
of disorders examined in order to continue to examine whether less 
common targets or populations profit as much as the targets examined in 
meta-analyses to date. Related, studies are needed that explicitly test 
multiple types of diagnoses and targets simultaneously (as opposed to in 
isolation and then combining at the meta-analytic level) in order to more 
thoroughly test the degree to which ACT can successfully be applied 
transdiagnostically. This later point first needs to be examined in 
outcome studies before being examined in meta-analyses. 
Given that effects observed in all studies and meta-analyses are 
dependent on multiple factors and conditions, we further examined the 
controlled effect sizes with respect to functional outcomes and not 
simply symptom-based outcomes. From the onset, ACT authors have 
stipulated that the goal of ACT is not reduction of internal states 
(although that may happen) but promoting functioning and well-being. 
This is predicated on the fact that mental health and well-being are not 
Table 3 (continued ) 
Meta-analysis Number of 
Comparisons 
Outcome cluster Comparison 
group 






Linardon et al. (2019) 3 Other Conditions: Eating Disorders WL Post 0.5 Significant 69.1 
Notes: The table presents the outcome clusters as we reported them in the result section. The category “other conditions” includes all psychological disorders other than 
anxiety, depression, substance abuse, and pain. The psychological diagnoses are specified behind the respective colon. The category “other outcomes” includes 
different secondary outcomes such as well-being, psychological flexibility, and quality of life. The effect sizes are if not other specified given in hedge’s g. The sig-
nificance of the effect size was determined by the authors of the original meta-analysis by indicating a p-value below .05, or 0.01 or 0.001, or by reporting the 
confidence interval. CBT (Cognitive Behavior Therapy), TAU (Treatment as Usual), WL (Waitlist), FU (Follow-up). 
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simply the opposite of symptoms (Keyes, 2005). Thus, while they are 
partially related, it is possible that an individual can have a high level of 
internal symptoms and high level of well-being just as it is possible that 
one can be anxiety-free and have low levels of well-being. Furthermore, 
ACT theory explicitly states that successful treatment promotes psy-
chological flexibility (Hayes et al., 2012; Hayes, Luoma, Bond, Masuda, 
& Lillis, 2006). Based on 20 meta-analyses, this review found that 
controlled effect sizes for ACT are small to medium on quality of life, 
small to large on psychological flexibility (though one meta-analysis did 
not report superior meta-analytic effects for psychological flexibility), 
and small to medium on measures of well-being, functioning, and 
disability. The somewhat higher controlled effect sizes observed for 
these outcomes in comparison to outcomes of symptoms can be inter-
preted as consistent with theory. It should be noted, however, that 
although these are controlled effect sizes, the magnitude of the differ-
ence was significant in 50% of the comparisons. It remains an open 
theoretical and empirical question as to the best way to define, assess, 
and capture successful intervention change. We remain mindful of the 
fact that these effects are often based on questionnaires and thus are 
subject to various biases. That said, this is common across studies and 
meta-analyses and so it can be assumed that these effects are held largely 
constant. 
We also examined the controlled effect sizes with respect to control 
conditions, with the assumption that effect sizes vary as a function of the 
comparison condition. When examining this contextual factor, we found 
small to large effect sizes for ACT compared to non-active control (e.g., 
waitlist), passive interventions (e.g., placebo), or a combination. With a 
few exceptions, ACT was either non-significantly different to or superior 
to other active interventions including treatment as usual, and a com-
bination of various active interventions. ACT was generally not statis-
tically different from CBT, although ACT was found to be more 
efficacious than CBT in a minority of meta-analyses (e.g., Ruiz, 2012). 
These results are consistent with previous studies (A-Tjak et al., 2015). 
Although different types of comparison groups are used for different 
purposes, we agree with others that testing and isolating processes of 
change (e.g., psychological flexibility, etc.) are more pressing research 
priorities than comparative trials testing two different treatments to 
determine if one is more efficacious. Naturally, these types of studies are 
not mutually exclusive, but future studies need to focus on common and 
unique processes, contexts, and procedures irrespective of the type of 
group design or even single-subject experimental designs (Gloster et al., 
2017; Levin, Hildebrandt, Lillis, & Hayes, 2012; Villanueva et al., 2019; 
Villatte et al., 2016). 
This review is subject to some important limitations. First, as 
aforementioned, there was a “double dipping” issue, where some studies 
were used for several comparisons and in more than one meta-analysis. 
Thus, some of the effects from individual studies may factor more than 
others. This was more likely to occur with older meta-analyses because 
newer ones have a wider range of published ACT trials from which to 
include studies. It remains unclear whether this “double-dipping” results 
in an overestimation, underestimation, or has a negligible effect on 
meta-analytic evidence. Future meta-analyses are encouraged to care-
fully consider this issue when selecting studies. A second limitation is 
that there were differences in terms of quality between the meta- 
analyses included, but we were not able to balance these differences. 
Some meta-analyses had inconsistencies regarding how many studies 
were included in a comparison. In several, it was unclear which studies 
were included, and in some the outcome measures were not listed. As 
reflected in the AMSTAR-2 assessment, several study details were 
missing and, in some case, incomplete. It is possible that some of these 
details were implemented in the studies, but not reported. Irrespective, 
future meta-analyses are strongly encouraged to be explicit about these 
methodological issues. Finally, meta-analyses are not without problems. 
Although meta-analyses allow summarization of effects, the observed 
effect sizes need to be contextualized. In this study we attempted to do 
this by examining the heterogeneity of effects across categories of target 
conditions, outcome variable, comparison group, and “double dipping.” 
Other factors impacting the heterogeneity of effect sizes are probable 
and future research should try to better capture these. Finally, individual 
meta-analyses constituted their groups differently (e.g., what patients 
make up “transdiagnostic” or which treatment is used in “TAU”) such 
that observed differences between meta-analyses within these labels 
may differ in part due to these contextual factors. 
These limitations notwithstanding, the present review found that 
ACT is efficacious for a wide range of intervention targets and outcomes. 
Further, ACT can be considered as efficacious as traditional CBT and 
more efficacious than other active comparisons. Future studies are 
strongly recommended to examine change processes including different 
trajectories of change and include (additional) outcomes of functioning 
and well-being. 
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Öst, L. G. (2008). Efficacy of the third wave of behavioral therapies: A systematic review 
and meta-analysis. Behaviour Research and Therapy, 46(3), 296–321. https://doi.org/ 
10.1016/j.brat.2007.12.005 
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